Latest news
FDA Fast-Tracks Psychedelic Research After Trump’s Executive Order — CMPS, HELP Stocks Gain - StocktwitsStocktwits · Sat, 08 Aug 2026 09:55:53 GMTCompass Pathways (NASDAQ:CMPS) Cut to Strong Sell at Wall Street Zen - MarketBeatMarketBeat · Sat, 08 Aug 2026 05:52:41 GMTCOMPASS Pathways (CMPS) Could Be 45% Below Fair Value On VA Trial Collaboration - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 19:11:43 GMTCOMPASS Pathways (CMPS) Stock Looks Stretched Following Its 214% One Year Run - simplywall.stsimplywall.st · Fri, 07 Aug 2026 17:45:21 GMTCMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial - StocktwitsStocktwits · Fri, 07 Aug 2026 15:54:57 GMTCOMPASS Pathways plc SEC Filing (Aug 7, 2026) - Stock TitanStock Titan · Fri, 07 Aug 2026 15:36:48 GMTA Quick Look at Today's Ratings for COMPASS Pathways(CMPS.US), With a Forecast Between $18 to $65 - MoomooMoomoo · Fri, 07 Aug 2026 13:00:02 GMTDFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - StocktwitsStocktwits · Fri, 07 Aug 2026 06:25:40 GMT